Phase 4
Completed N=88
Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression
Source: ClinicalTrials.gov NCT00200902 ↗Enrolled (actual)
88
Serious AEs
0.0%
Results posted
Apr 2019
Primary outcomePrimary: Response as Assessed by Participants' Change in Depression Rating — 17; 11; 1; 9 Participants
◆ Published Evidence
Established
86citations · ~7 / year
Role of pill-taking, expectation and therapeutic alliance in the placebo response in clinical trials for major depression.
Summary
This study will use measurements of depression symptoms and brain activity to determine what factors may influence an individual's response to treatment for depression.
Linked Publications
-
Role of pill-taking, expectation and therapeutic alliance in the placebo response in clinical trials for major depression.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Response as Assessed by Participants' Change in Depression Rating |
17; 11; 1; 9; 9; 0 | — |
| PRIMARY Average Change in 3 Weeks of Participant Treatment Expectations |
3.55; 3.94; 3.17 | — |
| PRIMARY Change in Hamilton Depression Assessment Score |
-0.46; -0.36; -0.05; -10.05; -7.59; -1.37 | — |
Eligibility Criteria
Inclusion Criteria
- Clinical diagnosis of unipolar major depression
Exclusion Criteria
- Substance abuse
- Psychotic disorder
- History of severe head trauma
Data sourced from ClinicalTrials.gov (NCT00200902) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.